New hope for advanced nose and throat cancer with combo therapy

NCT ID NCT07258979

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug (YL201) combined with an immunotherapy (toripalimab), with or without chemotherapy (cisplatin), in people whose nasopharyngeal cancer has come back or spread. The goal is to see if the combination is safe and helps control the cancer. About 202 adults with advanced disease will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT OR METASTATIC NASOPHARYNGEAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Affiliated Cancer Hospital and Institute of Guangzhou Medical University

    NOT_YET_RECRUITING

    Guangzhou, Guangdong, China

  • Chongqing University Cancer Hospital

    NOT_YET_RECRUITING

    Chongqing, Chongqing Municipality, China

  • Dongguan People's Hospital

    NOT_YET_RECRUITING

    Dongguan, Guangdong, China

  • Fudan University Shanghai Cancer Center

    NOT_YET_RECRUITING

    Shanghai, Shanghai Municipality, China

  • Fujian Cancer Hospital

    NOT_YET_RECRUITING

    Fuzhou, Fujian, China

  • Guangxi Medical University Cancer Hospital

    NOT_YET_RECRUITING

    Nanning, Guangxi, China

  • Hunan Cancer Hospital

    NOT_YET_RECRUITING

    Changsha, Hunan, China

  • Jiangmen Central Hospital

    NOT_YET_RECRUITING

    Jiangmen, Guangdong, China

  • Jiangxi Cancer Hospital

    NOT_YET_RECRUITING

    Nanchang, Jiangxi, China

  • Sichuan Cancer Hospital

    NOT_YET_RECRUITING

    Chengdu, Sichuan, China

  • Sun Yat-sen University Cancer Center

    RECRUITING

    Guangzhou, Guangdong, China

  • The First Affiliated Hospital of Guangdong Pharmaceutical University

    NOT_YET_RECRUITING

    Guangzhou, Guangdong, China

  • The First Affiliated Hospital of Hainan Medical University

    NOT_YET_RECRUITING

    Haikou, Hainan, China

  • The First Affiliated Hospital of Nanchang University

    NOT_YET_RECRUITING

    Nanchang, Jiangxi, China

  • The First Affiliated Hospital of Xiamen University

    NOT_YET_RECRUITING

    Xiamen, Fujian, China

  • The Second Affiliated Hospital of Guilin Medical University

    NOT_YET_RECRUITING

    Guilin, Guangxi, China

  • Yuebei People's Hospital

    NOT_YET_RECRUITING

    Shaoguan, Guangdong, China

  • Yunnan Cancer Hospital

    NOT_YET_RECRUITING

    Kunming, Yunnan, China

  • Zhangzhou Municiple Hospital of Fujian Province

    NOT_YET_RECRUITING

    Zhangzhou, Fujian, China

  • Zhejiang Cancer Hospital

    NOT_YET_RECRUITING

    Hangzhou, Zhejiang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.